Precision Radiation Oncology最新文献

{"title":"Dosimetric and Radiobiological Impact of Flattening Filter-Free Beam and Dose Calculation Algorithm Using RapidArc Plans for Cervical Cancer Treatment.","authors":"Sumanta Manna, Sharad Singh, Pramod Kumar Gupta, Ragul T","doi":"10.1002/pro6.1207","DOIUrl":"10.1002/pro6.1207","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study is to quantify the potential benefits of a flattening filter-free (FFF) beam and implement a dose-computation algorithm for cervical radiotherapy through dosimetric and radiobiological analyses using RapidArc.</p><p><strong>Methods: </strong>Thirty-three patients were enrolled, and four RapidArc plans were created for each patient using a dual-arc flattening filter and 6-MV FFF photon beams for the two calculation algorithms. Homogeneity index (HI), conformity index (CI), target coverage, monitor units (MUs), and organ-at-risk (OAR) dosimetric characteristics were compared between the plans. Radiobiological characteristics and normal tissue complication probability (NTCP) scores were computed for the OAR using different biological models.</p><p><strong>Results: </strong>No significant differences were observed in the D_max, D_98%, and CI in the planning target volume (PTV). Both computations estimated a significant difference in V_95%, D_2%, and HI for the PTV. Furthermore, the FFF beam showed a significant increase in the MUs and a significant reduction in V_30% for the femoral heads. The NTCP score showed a significant increase in the late effects on the bladder, rectum, and bowel with FFF beams.</p><p><strong>Conclusion: </strong>The current study recommends FFF beams for better conformity, comparable dose coverage for the target, and OAR sparing invariable to the dose computation algorithm. The difference in the NTCP score for OAR was minimal with the FFF beam.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"7 1","pages":"197-206"},"PeriodicalIF":0.0,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44177666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Auto-segmentation of the clinical target volume using a domain-adversarial neural network in patients with gynaecological cancer undergoing postoperative vaginal brachytherapy.","authors":"Junfang Yan, Xue Qin, Caixia Qiao, Jiawei Zhu, Lina Song, Mi Yang, Shaobin Wang, Lu Bai, Zhikai Liu, Jie Qiu","doi":"10.1002/pro6.1206","DOIUrl":"10.1002/pro6.1206","url":null,"abstract":"<p><strong>Purpose: </strong>For postoperative vaginal brachytherapy (POVBT), the diversity of applicators complicates the creation of a generalized auto-segmentation model, and creating models for each applicator seems difficult due to the large amount of data required. We construct an auto-segmentation model of POVBT using small data via domain-adversarial neural networks (DANNs).</p><p><strong>Methods: </strong>CT images were obtained postoperatively from 90 patients with gynaecological cancer who underwent vaginal brachytherapy, including 60 and 30 treated with applicators A and X, respectively. A basal model was devised using data from the patients treated with applicator A; next, a DANN model was constructed using these same 60 patients as well as 10 of those treated with applicator X through transfer learning techniques. The remaining 20 patients treated with applicator X comprised the validation set. The model's performance was assessed using objective metrics and manual clinical evaluation.</p><p><strong>Results: </strong>The DANN model outperformed the basal model on both objective metrics and subjective evaluation (<i>p</i><0.05 for all). The median DSC and 95HD values were 0.97 and 3.68 mm in the DANN model versus 0.94 and 5.61 mm in the basal model, respectively. Multi-centre subjective evaluation by three clinicians showed that 99%, 98%, and 81% of CT slices contoured by the DANN model were acceptable versus only 73%, 77%, and 57% of those contoured by the basal model. One clinician deemed the DANN model comparable to manual delineation.</p><p><strong>Conclusion: </strong>DANNs provides a realistic approach for the wide application of automatic segmentation of POVBT and can potentially be used to construct auto-segmentation models from small datasets.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"7 1","pages":"189-196"},"PeriodicalIF":0.0,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47219182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in radiotherapy for small-cell lung cancer.","authors":"Fujun Yang, Huan Zhao","doi":"10.1002/pro6.1205","DOIUrl":"10.1002/pro6.1205","url":null,"abstract":"<p><p>Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor that is prone to spread extensively. Compared to non-small-cell lung cancer (NSCLC), SCLC treatment progresses slowly. Although SCLC is highly sensitive to chemotherapy during the initial treatment, most patients still experience resistance and recurrence after receiving chemotherapy. A meta-analysis demonstrated that thoracic radiotherapy (TRT) improves overall survival in SCLC. The results of the CALGB and CONVERT trials provide evidence for the efficacy of once-daily high-dose TRT. TRT at 60 Gy administered twice daily significantly improved survival without increasing toxicity. The long-standing debate over the optimal timing of radiotherapy has not been fully resolved. SBRT has excellent local control rates and is a safe and effective treatment option for patients with stage I or II SCLC. Prophylactic cranial irradiation (PCI) is used to reduce treatment-related neurotoxicity to the extent that there has been a recent discussion on whether magnetic resonance imaging (MRI) monitoring can replace PCI. Radiotherapy combined with immunotherapy significantly improves the survival rate of patients with NSCLC; however, its clinical effectiveness has not been systematically explored in patients with SCLC. Therefore, we summarize the evolving therapeutic strategies, (TRT for limited stage-SCLC and consolidative TRT for extensive stage-SCLC) and improved radiotherapy techniques (role of SBRT in stage I or II node-negative SCLC, progress of PCI, and stereotactic radiosurgery), and discuss the possibilities and prospects of radiotherapy combined with immunotherapy for SCLC.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"7 1","pages":"207-217"},"PeriodicalIF":0.0,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47930366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated pretreatment squamous cell Carcinoma Antigen indicates unfavorable treatment outcomes in cervical cancer patients receiving definitive radiotherapy.","authors":"Dingchao Liu, Weiping Wang, Zheng Zeng, Xiaoliang Liu, Yuncan Zhou, Chen Wang, Xiaoyan Li, Ke Hu","doi":"10.1002/pro6.1202","DOIUrl":"10.1002/pro6.1202","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the prognostic value of pretreatment squamous cell carcinoma antigen (SCC Ag) levels for treatment failure prediction in patients with cervical cancer.</p><p><strong>Methods: </strong>A quantity of 985 patients satisfying the eligibility criteria were included, with a median follow-up duration of 63.7 months. The optimal cutoff value for pretreatment SCC Ag levels was verified by the receiver operating characteristic (ROC) curve. Five-year disease-free survival (DFS), overall survival (OS), and local control (LC) rates were evaluated utilizing the Kaplan-Meier method. Log-rank test and Cox proportional hazards model was implemented to recognize independent prognostic predictors.</p><p><strong>Results: </strong>The optimal pretreatment SCC Ag cutoff value was 8.85 ng/mL. Patients with pretreatment SCC Ag levels ≥ 8.85 ng/mL presented significantly inferior 5-year DFS (63.8% vs. 81.8%), OS (71.7% vs. 88.7%), and LC (80.5% vs. 91.0%) compared to those with levels < 8.85 ng/mL (all <i>p</i> < 0.001). The results of the multivariate analysis indicated that the pretreatment SCC Ag level was an independent predictor of treatment failure (HR,1.772; 95% CI, 1.366 to 2.299; <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Pretreatment SCC Ag is an effective prognostic factor in patients with cervical cancer undergoing definitive radiotherapy, with a ROC-identified cutoff value of 8.85 ng/mL and elevated SCC Ag indicates unfavorable outcomes.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"7 1","pages":"173-180"},"PeriodicalIF":0.0,"publicationDate":"2023-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42821106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-breast irradiation with lumpectomy cavity boost and regional nodal irradiation: Dosimetric comparison of 3D-CRT using sequential boost and dual partial-arc VMAT using simultaneous integrated boost.","authors":"Avinash Poojari, Shantanu Sapru, Rohini Khurana, Madhup Rastogi, Rahat Hadi, Ajeet Kumar Gandhi, Surendra Mishra, Anoop Srivastava, Avinav Bharati","doi":"10.1002/pro6.1203","DOIUrl":"10.1002/pro6.1203","url":null,"abstract":"<p><strong>Objective: </strong>To compare volumetric modulated arc therapy (VMAT) with simultaneous tumor bed boost (dpSIB-VMAT) to the whole breast and regional nodal irradiation (RNI) against standard three-dimensional conformal radiotherapy plus RNI with sequential tumor bed boost (3D-CRT-seqB).</p><p><strong>Methods: </strong>Thirty patients who underwent breast cancer surgery (BCS) with axillary lymph node dissection (ALND) were enrolled. Two plans were generated for each case: (1) dpSIB-VMAT, and (2) 3D-CRT-seqB plans. Planning target volume (PTV)-Breast and PTV-Nodes were prescribed at a dose of 50 Gy in 25 fractions in both plans. PTV-Boost was prescribed at a dose of 60 Gy in 25 fractions simultaneously in the dpSIB-VMAT plans, whereas it was planned sequentially in the 3D-CRT-seqB plans at 10 Gy in 5 fractions. Dosimetric parameters were compared between the two plans.</p><p><strong>Results: </strong>Both plans achieved the target coverage. D_mean of the heart was lower with dpSIB-VMAT in left-sided cases (7.17 ± 0.66 Gy vs. 10.12 ± 2.91 Gy; <i>t</i> = 4.02; <i>p</i> = 0.001). Ipsilateral mean lung dose (15.87 ± 1.40 Gy vs. 19.82 ± 3.20 Gy; <i>t</i> = 6.30; <i>p</i><0.001) was significantly lower but mean doses of the contralateral breast (4.30 ± 1.76 Gy vs. 1.48 ± 0.76 Gy; <i>t</i> = -7.84; <i>p</i><0.001), contralateral lung (3.86 ± 1.21 Gy vs. 0.96 ± 0.25 Gy; <i>t</i> = -13.13; <i>p</i><0.001) and esophagus (13.11 ± 2.63 Gy vs. 10.32 ± 3.56 Gy; <i>t</i> = -6.65; <i>p</i><0.001) were relatively higher with dpSIB-VMAT.</p><p><strong>Conclusion: </strong>Dosimetrically, dpSIB-VMAT reduced doses to the ipsilateral lung and heart (in left breast but not right breast cases) compared to 3D-CRT-seqB plans for adequate target coverage.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"7 1","pages":"118-127"},"PeriodicalIF":0.0,"publicationDate":"2023-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49301807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of Gafchromic^TM EBT4 film with clinical kV/MV photons and MeV electrons.","authors":"Fada Guan, Huixiao Chen, Emily Draeger, Yuting Li, Resat Aydin, Christopher J Tien, Zhe Chen","doi":"10.1002/pro6.1204","DOIUrl":"10.1002/pro6.1204","url":null,"abstract":"<p><strong>Objective: </strong>A newly developed Gafchromic^TM EBT4 film model was released recently. According to the vendor-stated specifications, this new model maintains major features of its more recent predecessor, EBT3, but has a great improvement in the signal-to-noise ratio (SNR). The purpose of this study was to fully characterize the EBT4 model by testing its dose response dependence on beam energy using clinical photon and electron beams and validating its improvement in SNR.</p><p><strong>Methods: </strong>In the beam energy dependence experiments, 6 MV and 15 MV photon beams, 6 MeV, 12 MeV and 20 MeV electron beams, 120 kVp and two 250 kVp x-ray beams (with different half-layer values) were selected, representing different clinical beam energies and radiation types. In the noise and SNR analyses, only the 6 MV photon beam was selected as the representative to compare between EBT4 and EBT3 models.</p><p><strong>Results: </strong>The energy dependence test results showed that there was a slight difference (<2% at most dose levels) in the dose response among the clinical MV photons and MeV electrons. However, a large deviation (>10%) in the dose response was found for the 120 kVp x-ray beam. For the two 250 kVp x-ray beams, the difference in the dose response was moderate (<5%), but not negligible. The noise and SNR results showed a reduced noise and strengthened SNR in EBT4.</p><p><strong>Conclusion: </strong>We conclude that the EBT4 film has a minimal energy dependence for MV photon and MeV electron beams but has a notable energy dependence for kilovoltage x-ray beams, and the vendor-stated features of the reduced noise and improved SNR in EBT4 are validated.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"7 1","pages":"84-91"},"PeriodicalIF":0.0,"publicationDate":"2023-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44908790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extensive-stage small cell lung cancer: Is prophylactic cranial irradiation necessary in the era of immunotherapy with MRI surveillance?","authors":"Yuanhu Yao, Nan Yao, Zhaohui Qin, Ji Ma, Jiaying Lu, Li Cui, Wanxi Qu, Shiwang Yuan, Shaodong Tong, Na Li, Hao Li","doi":"10.1002/pro6.1200","DOIUrl":"10.1002/pro6.1200","url":null,"abstract":"<p><strong>Objective: </strong>The role of prophylactic cranial irradiation (PCI) in treating extensive-stage small-cell lung cancer (ES-SCLC) has been controversial. This study aimed to comprehensively analyze the efficacy of PCI for the treatment of ES-SCLC under active brain magnetic resonance imaging (MRI) surveillance.</p><p><strong>Methods: </strong>Patients with ES-SCLC with no brain metastases (BM) confirmed by MRI at the time of diagnosis who responded well to first-line chemoimmunotherapy at three general hospitals were retrospectively included. Overall survival (OS), progression-free survival (PFS), and cumulative incidence of BM were compared between patients who underwent PCI and those who did not.</p><p><strong>Results: </strong>In total, 66 consecutive patients treated between March 2019 and December 2021 were included in our dataset. Seventeen patients underwent PCI (PCI group) and 49 patients did not (non-PCI group). In comparison with the non-PCI group, PCI did not provide OS (median OS: 18.53 <i>vs</i>. 17.35 months, <i>p</i> = 0.28) or PFS (median PFS: 8.61 <i>vs</i>. 7.56 months, <i>p</i> = 0.41) benefits. When death was counted as a competing risk, the difference in the cumulative incidence rate of BM was not statistically significant (1-year: 12.79% <i>vs</i>. 38.09%; <i>p</i> = 0.14).</p><p><strong>Conclusion: </strong>Compared to active MRI surveillance, first-line chemoimmunotherapy followed by PCI did not improve the prognosis of patients with ES-SCLC. Further studies are warranted to evaluate the therapeutic effects of PCI following chemoimmunotherapy.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"7 1","pages":"111-117"},"PeriodicalIF":0.0,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43371867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erb-(IL10)2 ameliorates radiation-induced skin injury through eliminate oxygen free radicals.","authors":"Jiahe Xu, Jiaxing Zhu, Qi Zhao, Jiao Xue, Songbing Qin","doi":"10.1002/pro6.1193","DOIUrl":"10.1002/pro6.1193","url":null,"abstract":"<p><strong>Objective: </strong>Radiation-induced skin injury (RISI) remains a serious concern during radiotherapy. IL-10 is considered as an immune suppressive cytokine by inhibiting the secretion of the proinflammatory cytokines in cells. The aim of this study was to evaluate the protective role of Erb (IL10) 2 against ionizing radiation.</p><p><strong>Methods: </strong>We fused Interleukin 10 (IL-10) dimer onto an anti-epidermal growth factor receptor antibody Cetuximab (Erbitux) to form a new bispecific protein Erb-(IL10)2. The protective effect and biological activity of Erb-(IL10)2 was measured in model of RISI.</p><p><strong>Results: </strong>Under the condition of 20 Gy irradiation, surviving cells in the IR group decreased significantly compared with the non-IR group (<i>p</i> = 0.0021). The survival rates of HaCaT (<i>p</i> = 0.0038) and WS1 (<i>p</i> = 0.0003) cells were significantly increased after IL-10 treatment. The apoptosis rates of HaCaT (<i>p</i> = 0.0048) and WS1 (<i>p</i> = 0.0074) cells in the IL-10 group were significantly lower compared to the NC group. Under 20 Gy irradiation conditions, IL-10 fusion protein reduced the level of reactive oxygen in HaCaT (<i>p</i> = 0.0046) and WS1 (<i>p</i><0.0001) cells compared to the control group. Relatively normal granular mitochondrial morphology was observed in the IL-10 group after 20 Gy X-ray irradiation compared with the NC group. Ater 35 Gy electron radiation, the levels of reactive oxygen species in the skin tissue of C57/B6 mice injected with IL-10 fusion protein were significantly lower than those in the PBS group (<i>p</i> = 0.001). Compared with the PBS group and the other IL-10 groups, the group treated with 0.2 mg/kg IL-10 showed a significant decrease in MDA level (<i>p</i> = 0.0024). Compared with the PBS group, the thickness of the stratum corneum in groups treated with 0.05, 0.1 and 0.2 mg/kg IL-10 decreased, and the skin appendages were well-preserved. In the group treated with 0.2 mg/kg IL-10, the skin tissue structure was still relatively intact, and the masson staining area was smaller than that of the PBS group.</p><p><strong>Conclusion: </strong>IL-10 plays a role in inhibiting radioactive fibrosis in radioactive skin injury. IL-10 has a protective effect on skin cell damage after ionizing radiation irradiation both in vitro and in vivo. Moreover, IL-10 plays a role in inhibiting radioactive fibrosis in radioactive skin injury.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"7 1","pages":"92-100"},"PeriodicalIF":0.0,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45230439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin metastasis in squamous cell cancer of cervix: A case report.","authors":"Xiujuan Zhao, Rui Chen, Qi Zhou","doi":"10.1002/pro6.1195","DOIUrl":"10.1002/pro6.1195","url":null,"abstract":"<p><p>Cervical cancer, the fourth most common cancer among females in the world, ranks the second in China. In advanced disease, metastases may be commonly present in the lungs, bones, liver and lymph nodes or elsewhere, but uncommon to the skin. In this report, a 63-year-old woman was diagnosed as stage IVB cervical squamous cell cancer in January 2021. The patient was scheduled for concurrent chemoradiotherapy; however, a metastatic lesion of skin was proved by biopsy during the process of treatment. She died 1 month after confirmed skin metastases. Cutaneous metastasis of cervical cancer may predict the mix of lymphatic and hematogenous metastasis and the rapid fatal termination.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"7 1","pages":"142-146"},"PeriodicalIF":0.0,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47564860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical study of analgesia in brachytherapy for cervical cancer","authors":"Liu Mei, Wu Hai‐Yan, Li Jian, Ou Meng‐Yu, Sun Shu‐Fang, Tang Ying, Zhao Xiu‐Juan","doi":"10.1002/pro6.1194","DOIUrl":"https://doi.org/10.1002/pro6.1194","url":null,"abstract":"Abstract Objective This study investigated the analgesic effects in patients with cervical cancer during brachytherapy. Methods In this prospective study, 100 patients with cervical cancer who were admitted to Chongqing University Cancer Hospital between July 2021 and April 2022 were randomly divided into an analgesia group (n = 50) and a control group (n = 50). The visual analog scale (VAS) scores at applicator placement‐T1, CT‐scan‐T2, and removal ‐T3, self‐rating anxiety scale (SAS) and self‐rating depression scale (SDS) scores before brachytherapy, short‐term clinical efficacy, and patient satisfaction were compared between the two groups. Results The VAS score of the analgesia group was significantly different at T1 (0 vs. 4.34±1.02, t = 67.40, p < 0.001), but not in the control group; however, there was no significant difference between the two groups at T2 ( t = ‐0.49, p = 0.623) and T3 ( t = ‐0.12, p = 0.912). The SAS and SDS scores first decreased and then increased in the analgesic group and increased in the control group with increasing brachytherapy time. Except for the first measurement, the differences between the two groups were statistically significant (all p < 0.001). The application of interstitial implantation ( p = 0.027), local efficacy ( p = 0.047), and patient satisfaction rates ( p = 0.025) were higher in the analgesic group than in the control group. Conclusion Analgesia can relieve pain, maintain physical and mental health, and improve outcomes and patient satisfaction rates for cervical cancer.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135776182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}